Advertisement
Advertisement
U.S. Markets open in 4 hrs 15 mins
S&P Futures
3,902.00 +4.25 (+0.11%) Dow Futures
31,241.00 +39.00 (+0.12%) Nasdaq Futures
11,838.00 -40.25 (-0.34%) Russell 2000 Futures
1,771.50 -3.40 (-0.19%) Crude Oil
110.35 +0.46 (+0.42%) Gold
1,845.10 +3.90 (+0.21%)
Merck & Co., Inc. (MRK)
NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
At close: 04:03PM EDT
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 92.09 |
| Open | 92.45 |
| Bid | 93.35 x 800 |
| Ask | 93.97 x 1400 |
| Day's Range | 92.47 - 94.08 |
| 52 Week Range | 70.89 - 94.92 |
| Volume | |
| Avg. Volume | 11,374,059 |
| Market Cap | 236.302B |
| Beta (5Y Monthly) | 0.46 |
| PE Ratio (TTM) | 33.01 |
| EPS (TTM) | 2.83 |
| Earnings Date | Apr 27, 2022 - May 02, 2022 |
| Forward Dividend & Yield | 2.76 (3.05%) |
| Ex-Dividend Date | Mar 14, 2022 |
| 1y Target Est | 95.73 |
- American City Business Journals
Merck to hire another 100 at newly expanded Cambridge research lab
Pharmaceutical giant Merck & Co. is expanding its presence in Greater Boston, this time with nearly 160,000 additional square feet at its Bent Street facility in Cambridge, where it plans to hire another 100 or so people over the next few years.
- Motley Fool
2 Top Biotech Stocks to Buy in May
Pharma stocks Merck (NYSE: MRK) and Johnson & Johnson (NYSE: JNJ) have gained 23% and 5%, respectively, year to date. Merck had five blockbuster products in 2021, including the top-selling cancer drug in the world, Keytruda.
- Zacks
Merck (MRK) Keytruda Gets EU Nod for Expanded Breast Cancer Use
The European Commission approves Merck's (MRK) Keytruda for high-risk early-stage TNBC, which expands its eligible patient population.
- Drug for advanced breast cancer available after NHS U-turns on decision to reject itThe Telegraph
- European Commission Approves KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced or Early-Stage Triple-Negative Breast Cancer at High Risk of RecurrenceBusiness Wire
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
